| Ytd | -50.83% | |
| 1y | -95.74% |
| Open | 3.93 | Prev Close | 3.83 | Low | 3.83 | High | 3.93 | Mkt Cap | 2.04M |
| Vol | 4.33K | Avg Vol | 251.74K | EPS | -112.73 | P/E | -0.03 | Forward P/E | N/A |
| Beta | 0.64 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 5.87 | 200-d Avg | 9.85 | 1yr Est | 0.00 |
DCOY News
Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, pr
Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular
Lead D-MAV demonstrates cross-viral family fusion inhibition, validating theplatform; opens a new pr
Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session
CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnol
Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-mark
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday&#
Gainers Abivax (NASDAQ:ABVX) shares increased by 36.0% to $130.74 during Tuesday's pre-market s
AeroVironment, Inc. (NASDAQ: AVAV) jumped 21.4% in pre-market trading after reporting strong financi
Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 284.8% to $11.39 during Monday
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 poi
Decoy Therapeutics Inc. (NASDAQ:DCOY) shares are trading higher. The company announced a $21 million
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday&
Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announ
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing PR Newswire HOUSTON
HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "De
Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for dis
CAMBRIDGE, Mass., June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnolo
hVIVO PLC's (AIM:HVO) consultancy contract with Decoy Therapeutics, announced on Monday, is a small
hVIVO PLC (AIM:HVO), the clinical development company specialising in human challenge trials, has si
Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral categor
Appointment deepens scientific leadership as Decoy advances its Designable Multi-Antiviral pipeline
CBO Peter Marschel to Lead HubXchange Roundtable on Computational Peptide Design CSO Dr. Barbara Hib
Decoy Therapeutics Inc. (DCOY) Discusses Corporate Overview and Pipeline Progress in Antiviral Drug
Highly differentiated AI-powered D-MAV discovery platform targeting drugdiscovery in the multi-billi
Live video webcast with Rick Pierce, Chief Executive Officer of Decoy Therapeutics, on Thursday, Apr
CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY)
ProMetic Life Sciences (OTCMKTS:PFSCF - Get Free Report) and Decoy Therapeutics (NASDAQ: DCOY - Get
Partnership supported by funding from Google Cloud will increase Decoy's computational peptide desig
CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ: DCOY), a preclinica